HIV-1 drug resistance among untreated patients in India: Current status.
HAART has dramatically improved survival and quality of life among people living with HIV and AIDS globally. However, drug resistant mutations of HIV are a great challenge to the benefits of HAART. Antiviral resistance can be mediated either by changes in the molecular target of therapy (the primary mechanism observed in HIV-1) or in other viral proteins that indirectly interfere with a drug's activity. Drug resistant mutations easily evolve in the presence of sub-optimal adherence. With the introduction of generic HAART, there has been a steep increase in the number of patients put on HAART in India. It should also be noted that since most patients pay for medications out of their own pockets, interruptions in therapy due to monetary constraints are not uncommon. There is little information on HIV drug resistance in resource constrained settings like India where the predominant circulating HIV-1 sub-type is C. The transmissibility of drug-resistant forms of the virus is also a major concern especially when formulating treatment guidelines. This article reviews published data available on the patterns of HIV-1 drug resistance among treatment naïve in India.
Pachamuthu
B
B
YRG Centre for AIDS Research and Education, Voluntary Health Services Campus, Taramani, Chennai-600113, India. bala@yrgcare.org
Shanmugam
S
S
Nagalingeswaran
K
K
Solomon
S S
SS
Solomon
S
S
Solomon
S
S
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology*; D019380:Anti-HIV Agents / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D024882:Drug Resistance, Viral / Q000235:genetics; D015497:HIV-1 / Q000145:classification / Q000187:drug effects*; D006801:Humans; D007194:India / Q000453:epidemiology; D009154:Mutation; D010349:Patient Compliance; D015995:Prevalence; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors